139 related articles for article (PubMed ID: 9215740)
1. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus.
Martineau D; Klump WM; McCormack JE; DePolo NJ; Kamantigue E; Petrowski M; Hanlon J; Jolly DJ; Mento SJ; Sajjadi N
Hum Gene Ther; 1997 Jul; 8(10):1231-41. PubMed ID: 9215740
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors.
Wilson CA; Ng TH; Miller AE
Hum Gene Ther; 1997 May; 8(7):869-74. PubMed ID: 9143913
[TBL] [Abstract][Full Text] [Related]
3. Development of enzyme-linked immunosorbent assay for detecting antibodies to replication-competent murine leukemia virus.
Kim S; Park EJ; Yu SS; Kim S
J Virol Methods; 2004 Jun; 118(1):1-7. PubMed ID: 15158062
[TBL] [Abstract][Full Text] [Related]
4. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells.
Long Z; Li LP; Grooms T; Lockey C; Nader K; Mychkovsky I; Mueller S; Burimski I; Ryan P; Kikuchi G; Ennist D; Marcus S; Otto E; McGarrity G
Hum Gene Ther; 1998 May; 9(8):1165-72. PubMed ID: 9625255
[TBL] [Abstract][Full Text] [Related]
5. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
[TBL] [Abstract][Full Text] [Related]
6. Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors.
Chen J; Reeves L; Cornetta K
Hum Gene Ther; 2001 Jan; 12(1):61-70. PubMed ID: 11177543
[TBL] [Abstract][Full Text] [Related]
7. Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR.
Allan DS; De Koven A; Wild A; Kamel-Reid S; Dubé ID
Leuk Lymphoma; 1996 Oct; 23(3-4):375-81. PubMed ID: 9031120
[TBL] [Abstract][Full Text] [Related]
8. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells.
Patience C; Takeuchi Y; Cosset FL; Weiss RA
J Virol; 1998 Apr; 72(4):2671-6. PubMed ID: 9525584
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences.
Otto E; Jones-Trower A; Vanin EF; Stambaugh K; Mueller SN; Anderson WF; McGarrity GJ
Hum Gene Ther; 1994 May; 5(5):567-75. PubMed ID: 8054374
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.
Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV
Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671
[TBL] [Abstract][Full Text] [Related]
12. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research.
Chen J; Reeves L; Sanburn N; Croop J; Williams DA; Cornetta K
Virology; 2001 Mar; 282(1):186-97. PubMed ID: 11259201
[TBL] [Abstract][Full Text] [Related]
13. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.
Printz M; Reynolds J; Mento SJ; Jolly D; Kowal K; Sajjadi N
Gene Ther; 1995 Mar; 2(2):143-50. PubMed ID: 7719931
[TBL] [Abstract][Full Text] [Related]
14. Detection of replication competent retrovirus and lentivirus.
Sastry L; Cornetta K
Methods Mol Biol; 2009; 506():243-63. PubMed ID: 19110631
[TBL] [Abstract][Full Text] [Related]
15. An improved method for detection of replication-competent retrovirus in retrovirus vector products.
Uchida E; Sato K; Iwata A; Ishii-Watabe A; Mizuguchi H; Hikata M; Murata M; Yamaguchi T; Hayakawa T
Biologicals; 2004 Sep; 32(3):139-46. PubMed ID: 15536044
[TBL] [Abstract][Full Text] [Related]
16. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors.
Dalba C; Klatzmann D; Logg CR; Kasahara N
Curr Gene Ther; 2005 Dec; 5(6):655-67. PubMed ID: 16457654
[TBL] [Abstract][Full Text] [Related]
17. General principles of retrovirus vector design.
Chang T; Yee JK
Methods Enzymol; 2012; 507():1-14. PubMed ID: 22365766
[TBL] [Abstract][Full Text] [Related]
18. High efficiency retroviral vectors that contain no viral coding sequences.
Yu SS; Kim JM; Kim S
Gene Ther; 2000 May; 7(9):797-804. PubMed ID: 10822307
[TBL] [Abstract][Full Text] [Related]
19. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
[TBL] [Abstract][Full Text] [Related]
20. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
